Laminate Medical Technologies

Company Overview

Snapshot

Founded in January 2012 by Eyal Orion and Tammy Gilon, Laminate Medical Technologies operates with 11–50 employees. The company has raised $24 million across six funding rounds from 17 investors. In April 2024, Tal Ventures participated in a funding round.

Business overview

Laminate Medical Technologies develops solutions to improve fistula use in dialysis patients. Its core product, VasQ External Support, is designed to reduce primary fistula failure rates and the need for repeat procedures in hemodialysis patients. The company serves the healthcare industry, specifically targeting hospitals, clinics, and healthcare providers with its medical device in the Health Tech & Life Sciences sector.

Strategic signal

In September 2024, VasQ Extravascular Support was granted Transitional Pass-Through (TPT) payment. This development is significant as it indicates regulatory and reimbursement progress, potentially accelerating market adoption and improving access to the device for patients requiring renal vascular procedures. For investors, this signals a positive trajectory for commercialization and revenue growth.

Company Intelligence Q&A

What is Laminate Medical Technologies' flagship product?

Laminate Medical Technologies' flagship product is VasQ External Support, an implanted device designed to address the high rate of primary fistula failure in dialysis patients.

When did VasQ receive FDA clearance?

Laminate Medical Technologies announced FDA clearance for its VasQ AVF creation device in September 2023.

Has VasQ been implanted in the US since FDA De Novo approval?

Yes, the first U.S. implantation of VasQ since FDA De Novo was granted occurred in January 2024.

What was a key finding from a randomized MRI-based study on VasQ?

A randomized MRI-based study in June 2022 revealed that VasQ External Support promotes more stable hemodynamics than standard AVFs.